Close menu

September 10th, 2021 | 12:43 CEST

NanoRepro, XPhyto Therapeutics, BioNTech, Valneva - The next biotech wave is rolling!

  • Biotechnology
Photo credits:

So far, vaccine manufacturers can maintain their high valuation because the next wave of new infections is rolling in. In Germany, tests will be subject to fees starting in October, making public life more expensive for those who want to participate. In surveys, most German citizens have expressed support for fee-based testing; probably, the populations here should be separated into "vaccinated" and "unvaccinated" to indicate general opinion accurately. Four interesting values benefit from the current situation.

time to read: 4 minutes | Author: André Will-Laudien
ISIN: NANOREPRO AG | DE0006577109 , XPHYTO THERAPEUTICS | CA98421R1055 , BIONTECH SE SPON. ADRS 1 | US09075V1026 , VALNEVA SE EO -_15 | FR0004056851

Table of contents:

    NanoRepro - Into the next wave with partner Viromed

    NanoRepro was already able to benefit strongly from the demand for tests in 2021. Now a consortium of investors seems to be positioning itself. NanoRepro's partner, the Viromed Group, recently took a minority stake in the Marburg-based Company. Arguably, this is the first step toward putting NanoRepro's high cash reserves to good use.

    Viromed's plans go further, however, as it subsequently became known that it intends to acquire a majority stake in NanoRepro through various contributions in kind. However, Viromed did not yet provide details on the plans. According to the latest data, the Viromed Group currently holds less than 30% of NanoRepro.

    Viromed is a high-growth partner from the environment of hospital operators and significantly expands the spectrum of NanoRepro. That brings renewed fantasy for the NanoRepro share. The share price recently rose to EUR 11.50 and is currently consolidating at the EUR 9 mark. In the medium term, there should be a significant appreciation here!

    XPhyto Therapeutics - Sales launch for the new 25-minute test

    XPhyto Therapeutics is making good progress with its PCR tests. The recently announced launch of its 25-minute COVID-19 PCR test "COVID-ID Lab" was successful. During the pilot project at the test centers in Berlin, the workflows and protocols for the rapid, efficient, and reliable COVID-ID Lab were optimized for deployment. These technical and operational insights are critical for the product launch and further sales to existing and new customers. Now the stage is set for large-scale commercialization.

    "We are extremely pleased with the results of the pilot project. The practical lessons learned, from training protocols to efficient workflows, are necessary to accelerate the growth of our sales force. These results demonstrate the success of our business strategy in rapid point-of-care diagnostics," said Wolfgang Probst (COO). In parallel to the pilot project, concepts and services are being developed with partners to offer modular testing and hygiene solutions for larger events such as concerts, sporting events and conferences. Regarding the discussion about applying the 3G or 2G rule, this comes just at the right time because, in Baden-Württemberg, public events can only be attended with an up-to-date PCR test. XPhyto is here to help with its cost-effective 25min test, as other authorities and governments will also make the switch from antigen to PCR testing in the coming months. XPhyto's partner in this business is BeoVita GmbH & Co. KG.

    XPhyto's timing for the late summer sales launch could not be better. Recently, the share has consolidated somewhat and, at CAD 1.60, is now in a very interesting buy zone from a chart perspective. It is also being traded in Germany with good turnover. A medium-term entry is worthwhile in the EUR 1.05 to 1.25 range - because the Company's pipeline is full to bursting.

    BioNTech - Booster vaccines ensure high order intake

    According to experts, the availability of Corona vaccines continues to increase significantly. By the end of 2021, 12 billion doses will have been produced. Developers are coming from a wide variety of continents. Chinese vaccines account for around half of this, with Western manufacturers producing the other half. Every third person on earth is completely vaccinated against the coronavirus.

    There are even surpluses of vaccines at the moment because governments want to be ready for the potential mutants in the fall and offer booster vaccinations. The US, Canada, the EU and the UK will have so many vaccine doses at the end of September that they could give about 500 million doses to other countries without further damage to their vaccination campaigns. In 2022, Pfizer CEO Albert Bourla expects production to increase further to four billion doses of the Comirnaty vaccine. A large portion is already being supplied to poorer countries, and there is also sufficient market supply for 2022. Currently, however, demand for vaccination is low due to a lack of government action.

    BioNTech shares are still floating on top of the wave, even if the price has given up 28% from the August high. The price-to-sales ratio is about 6, and the P/E ratio in 2021 is 8.5. The ratios are now attractive again, so in weakness, one should get in.

    Valneva - New ideas from France

    The share of the French-Austrian biotech Company Valneva SE has almost doubled on a monthly basis. The background is the growing hope that the Company's Corona vaccine will receive approval before the end of this year. Perhaps too late, many investors are asking?

    The vaccine peak is likely to be passed in the fall, and companies like BioNTtech and Moderna have already sold their wares. But this view may fall short in the case of Valneva. Their vaccine, which is currently being tested in a phase 3 trial in the UK, is the only one in Europe based on the classical method of dead viruses. Just as has been the case for years with vaccinations against influenza or hepatitis, it could become a big hit. It could win over people who have not yet been vaccinated because of their skepticism about the new mRNA vaccines.

    So there is a lot of speculation, but also plenty of imagination in the share. Since the summer of 2020, the share price has risen by 325%. That means that a lot of hope is already priced in. However, anyone looking for diversification from the well-known names is in good hands with Valneva. From a chart perspective, the value must first rise above EUR 25 again, and then it could continue to run.

    The stocks considered here are active in the environment of pandemic control. Vaccine manufacturers have been in demand for months and are now consolidating strongly. Test providers such as NanoRepro or XPhyto could experience a decent renaissance in the fall.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.

    Der Autor

    André Will-Laudien

    Born in Munich, he first studied economics and graduated in business administration at the Ludwig-Maximilians-University in 1995. As he was involved with the stock market at a very early stage, he now has more than 30 years of experience in the capital markets.

    About the author

    Related comments:

    Commented by Nico Popp on September 27th, 2023 | 07:10 CEST

    Rich as a Sheikh? Here is what's happening: Schott Pharma, BioNTech, Cardiol Therapeutics

    • Biotechnology
    • Pharma

    High-tech or add-on? When Schott Pharma's shares go public in Frankfurt on Thursday, investors are likely to have a clear opinion. The manufacturer of pharmaceutical packaging may be attracting significant interest precisely because its business model is clearly defined. But what sets Schott apart, and which companies in the pharmaceutical and biotech industry might also become interesting? We provide insights and deliver answers!


    Commented by Juliane Zielonka on September 22nd, 2023 | 06:50 CEST

    Cardiol Therapeutics, BioNTech, BYD - At top speed to new markets

    • Biotechnology
    • Pharma
    • Electromobility

    Cardiol Therapeutics is enjoying a remarkable development. The biotech company is now rolling out its ARCHER patient recruitment trial internationally at 35 participating centers. This accelerates research in the development of their therapy to combat myocarditis, a heart inflammation which has been associated with COVID-19 vaccination. For Cardiol Therapeutics, this represents an opportunity to get its therapy approved as an orphan drug. Approval is also at stake for BioNTech. With a multimillion-dollar funding boost, the Company is working on accelerated approval for a vaccine against a virus that caused quite a stir last year. The shortened development time is likely to impress investors. While business nations agree on fighting viruses, they disagree on commodities for the road. The EU would prefer to restrict BYD's successful sales on domestic roads - by imposing tariffs. BYD, meanwhile, is tapping into a completely different market.


    Commented by André Will-Laudien on September 18th, 2023 | 06:30 CEST

    Unbelievable! Hands off AI, biotech in rebound! Bayer, Defence Therapeutics, Morphosys

    • AI
    • Biotechnology
    • Investments

    The big fall decline is now over. It is always a difficult time, but the so-called "Triple Witching" went relatively smoothly this time. The European Central Bank (ECB), in its first interest rate meeting after the summer break, decided to raise key rates by another quarter point to 4.00%, up from the previous 3.75% in July. At the same time, it lowered its inflation forecast for 2025 and the outlook for economic growth in the Eurozone for the years 2023 to 2025. Economic risks are increasing, but inflation remains the determining factor for interest rates. Expectations that the US Federal Reserve (FED) will announce an interest rate pause at its next meeting on Wednesday have boosted confidence. Last week's big losers were the recently favoured AI stocks Nvidia, Microsoft and However, the biotech sector has recently started to climb again. Where are the opportunities for investors?